Table 2.

Final visit characteristics of patients undergoing intravitreal ranibizumab treatment

Subject	Final BCVA			CMT	Visual symptoms	Follow-up time (weeks)	Treatments (n)
	Snellen	Letters	Decimal
1	20/63	29	0.32	278	None	58	3
2	20/25	47	0.80	263	None	52	2
3	20/20	55	1.00	279	None	66	1
4	20/32	44	0.63	275	None	73	3
5	20/40	38	0.50	255	None	80	4
6	20/100	19	0.20	291	None	71	5

Abbreviations: BCVA, best-corrected visual acuity; CMT, central subfield thickness.